Your browser doesn't support javascript.
loading
Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children: A Case Series and Literature Review.
Article en En | MEDLINE | ID: mdl-36780635
BACKGROUND AND OBJECTIVE: We report our initial experience with intravitreal bevacizumab-bvzr, a bevacizumab biosimilar approved by the US Food and Drug Administration in 2019 and recently introduced by our institution for off-label ophthalmologic use in children. PATIENTS AND METHODS: This was an Institutional Review Board-approved single-institution retrospective case series of pediatric patients 21 years or younger who received at least one intravitreal injection of biosimilar bevacizumab-bvzr. RESULTS: Twelve eyes of 9 patients were identified as having received intravitreal bevacizumab-bvzr, with a total of 13 injections performed. Indications for injection included retinopathy of prematurity (7/13), choroidal neovascularization (3/13), retinal vein occlusion (2/13), and Coats disease (1/13). Following injection of bevacizumab-bvzr, all patients experienced a positive clinical response. No occurrences of postinjection inflammation, intraocular pressure anomalies, or endophthalmitis were observed with a median follow-up of 18 weeks. CONCLUSION: In the absence of controlled studies, this case series supports the use of intravitreal bevacizumab-bvzr as an anti-vascular endothelial growth factor therapy option, including in the pediatric population and resource-poor settings. [Ophthalmic Surg Lasers Imaging Retina 2023;54:84-88.].
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Biosimilares Farmacéuticos Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: Ophthalmic Surg Lasers Imaging Retina Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Biosimilares Farmacéuticos Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: Ophthalmic Surg Lasers Imaging Retina Año: 2023 Tipo del documento: Article